ArticleAnnals of hematology2026
Epidemiological trends and burden projections of childhood leukemia in China: age-stratified analysis and impact of COVID-19 from 1990 to 2035.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To analyze the incidence, mortality, and disease burden (disability-adjusted life year, DALY rate) of leukemia in children aged 0–14 years in China from 1990 to 2021. Based on the Chinese leukemia surveillance data in the Global Burden of Disease database from 1990 to 2021. The Estimated Annual Percentage Change (EAPC) and Bayesian Age–Period–Cohort (BAPC) prediction models were used to evaluate the trends of incidence, mortality and DALY in different strata and predict them to 2035. The EAPC was used to quantify the annual trends of incidence, mortality and DALY rates, and the BAPC model was used to decompose the independent effects of age, period and birth cohort on the burden of disease. The incidence of childhood leukemia in 2021 decreased by 10.8% compared with 1990, together with this, the mortality rate (76.9%) and DALY rate (76.9%) decreased significantly. After the COVID-19 pandemic, the incidence rates in the 1–5 month group and the 6–11 month group increased by 63.7% and 62.5%, respectively, while those in the 12–23 month group and the 2–4 year group decreased by 23.1% and 58.1%, respectively. Acute lymphocytic leukemia accounted for the highest proportion, and the incidence rate in male newborns was higher than that in female newborns. It is predicted that by 2035, the incidence, mortality and DALY rates will further decline. The burden of childhood leukemia is declining overall in China, but attention should be paid to fluctuations in specific age groups and gender differences to optimize early screening and classification treatment programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.